Unanswered questions on the use of hydrocortisone, ascorbic acid, and thiamine therapy in sepsis and septic shock

Abstract Purpose To evaluate current evidence on the utility of hydrocortisone, ascorbic acid, and thiamine (HAT) therapy for the management of septic shock. Summary The following keyword search terms were utilized in PubMed to identify relevant articles: ascorbic acid, thiamine, hydrocortisone, sho...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of health-system pharmacy 2022-09, Vol.79 (19), p.1626-1633
Hauptverfasser: Ragoonanan, David, Tran, Nicolas, Modi, Veeshal, Morgan Nickelsen, Paige
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1633
container_issue 19
container_start_page 1626
container_title American journal of health-system pharmacy
container_volume 79
creator Ragoonanan, David
Tran, Nicolas
Modi, Veeshal
Morgan Nickelsen, Paige
description Abstract Purpose To evaluate current evidence on the utility of hydrocortisone, ascorbic acid, and thiamine (HAT) therapy for the management of septic shock. Summary The following keyword search terms were utilized in PubMed to identify relevant articles: ascorbic acid, thiamine, hydrocortisone, shock, and critical care. Articles relevant to HAT therapy in patients with septic shock were selected. Retrospective cohorts and randomized controlled trials were included in this review; case reports/series were excluded. Data from included studies illustrating the use of HAT therapy for the management of sepsis and septic shock, including data on time to HAT therapy initiation, severity of illness at baseline, duration of vasopressor therapy, progression of organ failure, and mortality, were evaluated. Conclusion The utilization of HAT therapy for the management of sepsis and septic shock remains controversial. Hemodynamic benefits have been shown to be most pronounced when HAT therapy is initiated earlier. Future studies directed at earlier initiation may be necessary to confirm this theory.
doi_str_mv 10.1093/ajhp/zxac169
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2676926311</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ajhp/zxac169</oup_id><sourcerecordid>2676926311</sourcerecordid><originalsourceid>FETCH-LOGICAL-c323t-d0defdb77620bf7c8acd8351dc74812b0ba037ba9ad15897b40cf811624ec1073</originalsourceid><addsrcrecordid>eNp9kL1PwzAQxS0EonxtzMgbDA2c7SZORlTxJVVigTlybEd1ae3gSwTlr8elhZHp3ul-96T3CDlncM2gEjdqMe9uvj6VZkW1R45YLvKMVwD7SYOsMg4lH5FjxAUA4yUUh2QkcgkMyvyIvL965fHDRmvo-2Cxd8EjDZ72c0sHtDS0dL42MegQe4fB2zFVmJbGaaq0M2n1JtFOrZy3m7eoujV1nqLt0OHPOck-8TgP-u2UHLRqifZsN0_I6_3dy_Qxmz0_PE1vZ5kWXPSZAWNb00hZcGhaqUulTSlyZrSclIw30CgQslGVMiwvK9lMQLclYwWfWJ2CixNytfXtYvhJVq8cartcKm_DgDUvZFHxQjCW0PEW1TEgRtvWXXQrFdc1g3pTcr0pud6VnPCLnfPQrKz5g39bTcDlFghD97_VNypEiNQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2676926311</pqid></control><display><type>article</type><title>Unanswered questions on the use of hydrocortisone, ascorbic acid, and thiamine therapy in sepsis and septic shock</title><source>Oxford Journals</source><creator>Ragoonanan, David ; Tran, Nicolas ; Modi, Veeshal ; Morgan Nickelsen, Paige</creator><creatorcontrib>Ragoonanan, David ; Tran, Nicolas ; Modi, Veeshal ; Morgan Nickelsen, Paige</creatorcontrib><description>Abstract Purpose To evaluate current evidence on the utility of hydrocortisone, ascorbic acid, and thiamine (HAT) therapy for the management of septic shock. Summary The following keyword search terms were utilized in PubMed to identify relevant articles: ascorbic acid, thiamine, hydrocortisone, shock, and critical care. Articles relevant to HAT therapy in patients with septic shock were selected. Retrospective cohorts and randomized controlled trials were included in this review; case reports/series were excluded. Data from included studies illustrating the use of HAT therapy for the management of sepsis and septic shock, including data on time to HAT therapy initiation, severity of illness at baseline, duration of vasopressor therapy, progression of organ failure, and mortality, were evaluated. Conclusion The utilization of HAT therapy for the management of sepsis and septic shock remains controversial. Hemodynamic benefits have been shown to be most pronounced when HAT therapy is initiated earlier. Future studies directed at earlier initiation may be necessary to confirm this theory.</description><identifier>ISSN: 1079-2082</identifier><identifier>EISSN: 1535-2900</identifier><identifier>DOI: 10.1093/ajhp/zxac169</identifier><identifier>PMID: 35701085</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><ispartof>American journal of health-system pharmacy, 2022-09, Vol.79 (19), p.1626-1633</ispartof><rights>American Society of Health-System Pharmacists 2022. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2022</rights><rights>American Society of Health-System Pharmacists 2022. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c323t-d0defdb77620bf7c8acd8351dc74812b0ba037ba9ad15897b40cf811624ec1073</citedby><cites>FETCH-LOGICAL-c323t-d0defdb77620bf7c8acd8351dc74812b0ba037ba9ad15897b40cf811624ec1073</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1583,27915,27916</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35701085$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ragoonanan, David</creatorcontrib><creatorcontrib>Tran, Nicolas</creatorcontrib><creatorcontrib>Modi, Veeshal</creatorcontrib><creatorcontrib>Morgan Nickelsen, Paige</creatorcontrib><title>Unanswered questions on the use of hydrocortisone, ascorbic acid, and thiamine therapy in sepsis and septic shock</title><title>American journal of health-system pharmacy</title><addtitle>Am J Health Syst Pharm</addtitle><description>Abstract Purpose To evaluate current evidence on the utility of hydrocortisone, ascorbic acid, and thiamine (HAT) therapy for the management of septic shock. Summary The following keyword search terms were utilized in PubMed to identify relevant articles: ascorbic acid, thiamine, hydrocortisone, shock, and critical care. Articles relevant to HAT therapy in patients with septic shock were selected. Retrospective cohorts and randomized controlled trials were included in this review; case reports/series were excluded. Data from included studies illustrating the use of HAT therapy for the management of sepsis and septic shock, including data on time to HAT therapy initiation, severity of illness at baseline, duration of vasopressor therapy, progression of organ failure, and mortality, were evaluated. Conclusion The utilization of HAT therapy for the management of sepsis and septic shock remains controversial. Hemodynamic benefits have been shown to be most pronounced when HAT therapy is initiated earlier. Future studies directed at earlier initiation may be necessary to confirm this theory.</description><issn>1079-2082</issn><issn>1535-2900</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kL1PwzAQxS0EonxtzMgbDA2c7SZORlTxJVVigTlybEd1ae3gSwTlr8elhZHp3ul-96T3CDlncM2gEjdqMe9uvj6VZkW1R45YLvKMVwD7SYOsMg4lH5FjxAUA4yUUh2QkcgkMyvyIvL965fHDRmvo-2Cxd8EjDZ72c0sHtDS0dL42MegQe4fB2zFVmJbGaaq0M2n1JtFOrZy3m7eoujV1nqLt0OHPOck-8TgP-u2UHLRqifZsN0_I6_3dy_Qxmz0_PE1vZ5kWXPSZAWNb00hZcGhaqUulTSlyZrSclIw30CgQslGVMiwvK9lMQLclYwWfWJ2CixNytfXtYvhJVq8cartcKm_DgDUvZFHxQjCW0PEW1TEgRtvWXXQrFdc1g3pTcr0pud6VnPCLnfPQrKz5g39bTcDlFghD97_VNypEiNQ</recordid><startdate>20220922</startdate><enddate>20220922</enddate><creator>Ragoonanan, David</creator><creator>Tran, Nicolas</creator><creator>Modi, Veeshal</creator><creator>Morgan Nickelsen, Paige</creator><general>Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20220922</creationdate><title>Unanswered questions on the use of hydrocortisone, ascorbic acid, and thiamine therapy in sepsis and septic shock</title><author>Ragoonanan, David ; Tran, Nicolas ; Modi, Veeshal ; Morgan Nickelsen, Paige</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c323t-d0defdb77620bf7c8acd8351dc74812b0ba037ba9ad15897b40cf811624ec1073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ragoonanan, David</creatorcontrib><creatorcontrib>Tran, Nicolas</creatorcontrib><creatorcontrib>Modi, Veeshal</creatorcontrib><creatorcontrib>Morgan Nickelsen, Paige</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of health-system pharmacy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ragoonanan, David</au><au>Tran, Nicolas</au><au>Modi, Veeshal</au><au>Morgan Nickelsen, Paige</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Unanswered questions on the use of hydrocortisone, ascorbic acid, and thiamine therapy in sepsis and septic shock</atitle><jtitle>American journal of health-system pharmacy</jtitle><addtitle>Am J Health Syst Pharm</addtitle><date>2022-09-22</date><risdate>2022</risdate><volume>79</volume><issue>19</issue><spage>1626</spage><epage>1633</epage><pages>1626-1633</pages><issn>1079-2082</issn><eissn>1535-2900</eissn><abstract>Abstract Purpose To evaluate current evidence on the utility of hydrocortisone, ascorbic acid, and thiamine (HAT) therapy for the management of septic shock. Summary The following keyword search terms were utilized in PubMed to identify relevant articles: ascorbic acid, thiamine, hydrocortisone, shock, and critical care. Articles relevant to HAT therapy in patients with septic shock were selected. Retrospective cohorts and randomized controlled trials were included in this review; case reports/series were excluded. Data from included studies illustrating the use of HAT therapy for the management of sepsis and septic shock, including data on time to HAT therapy initiation, severity of illness at baseline, duration of vasopressor therapy, progression of organ failure, and mortality, were evaluated. Conclusion The utilization of HAT therapy for the management of sepsis and septic shock remains controversial. Hemodynamic benefits have been shown to be most pronounced when HAT therapy is initiated earlier. Future studies directed at earlier initiation may be necessary to confirm this theory.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>35701085</pmid><doi>10.1093/ajhp/zxac169</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1079-2082
ispartof American journal of health-system pharmacy, 2022-09, Vol.79 (19), p.1626-1633
issn 1079-2082
1535-2900
language eng
recordid cdi_proquest_miscellaneous_2676926311
source Oxford Journals
title Unanswered questions on the use of hydrocortisone, ascorbic acid, and thiamine therapy in sepsis and septic shock
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T17%3A43%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Unanswered%20questions%20on%20the%20use%20of%20hydrocortisone,%20ascorbic%20acid,%20and%20thiamine%20therapy%20in%20sepsis%20and%20septic%20shock&rft.jtitle=American%20journal%20of%20health-system%20pharmacy&rft.au=Ragoonanan,%20David&rft.date=2022-09-22&rft.volume=79&rft.issue=19&rft.spage=1626&rft.epage=1633&rft.pages=1626-1633&rft.issn=1079-2082&rft.eissn=1535-2900&rft_id=info:doi/10.1093/ajhp/zxac169&rft_dat=%3Cproquest_cross%3E2676926311%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2676926311&rft_id=info:pmid/35701085&rft_oup_id=10.1093/ajhp/zxac169&rfr_iscdi=true